Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 MillionRetinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Rel.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results Lexington, Mass. - March 9, 2022 - Keros. | March 9, 2022
11.02.2022 - LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering .
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer - read this article along with other careers information, tips and advice on BioSpace